The role of genotype and diet in shaping gut microbiome in a genetic Vitamin A deficient mouse model
Multi-factors have been reported to have an effect on the intestine microbiome, together with genotype, age, eating regimen, and diet. Nevertheless, few experiences have investigated the relative capability of various elements to form the intestine microbiome in a single research.
Our design used a genetic Vitamin A poor mouse mannequin, the Rbp4-/- mouse, feeding with the low Vitamin A diets at totally different ages of initiation (four or 7 weeks) for 28 days. Fecal samples had been collected for bacterial profiling at seven time factors after eating regimen controlling.
With RBP4 depletion, Akkermansia decreased and Bacteroides elevated, whereas Desulfovibrio, Barnesiella, Clostridium_XlVa, and Lactobacillus fluctuated. The bacterial group swiftly adjusted with the Vitamin A-deficient eating regimen administration and step by step modified (e.g., lower of Barnesiella and improve of Desulfovibrio).
Age exerted a comparatively weaker however long-last affect. At an earlier age to feed a Vitamin-A poor eating regimen, a better microbial dysbiosis index (MDI) will probably be valued. Of notice, the shaping results of eating regimen and age on the bacterial group various with the distinction of genotype, which could point out a better function of genotype than eating regimen and age in shaping the intestine microbiome.
Two Kinds of Mouse Fashions for Sarcopenia Analysis: Senescence Acceleration and Genetic Modification Fashions
Sarcopenia results in lack of skeletal muscle mass, high quality, and energy as a consequence of growing old; it was lately given a illness code (Worldwide Classification of Illnesses, Tenth Revision, Medical Modification, M62.84). Consequently, lately, sarcopenia-related analysis has elevated.
As well as, numerous research in search of to forestall and deal with sarcopenia by figuring out the varied mechanisms associated to the discount of skeletal muscle properties have been carried out. Earlier research have recognized muscle synthesis and breakdown; investigating them has generated proof for stopping and treating sarcopenia.
Mouse fashions are nonetheless essentially the most helpful ones for figuring out mechanisms underlying sarcopenia by correlations and interventions involving particular genes and their phenotypes. Mouse fashions used to check sarcopenia typically induce muscle atrophy by hindlimb unloading, denervation, or immobilization.
Although it’s much less regularly used, the senescence-accelerated mouse may also be helpful for sarcopenia analysis. Herein, we focus on instances the place senescence-accelerated and genetically engineered mouse fashions had been utilized in sarcopenia analysis and totally different views to make use of them.
CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Mannequin of Hemophilia A
Hemophilia A (HA), a standard bleeding dysfunction attributable to a deficiency of coagulation issue VIII (FVIII), has lengthy been thought-about a beautiful goal for gene remedy research. Nevertheless, full-length F8 cDNA can’t be packaged effectively by adeno-associated virus (AAV) vectors.
Because the second most prevalent mutation inflicting extreme HA, F8 intron 1 inversion (Inv1) is attributable to an intrachromosomal recombination, leaving the vast majority of F8 (exons 2-26) untranscribed. In concept, the truncated gene could possibly be rescued by integrating a promoter and the coding sequence of exon 1. To check this technique in vivo, we generated an HA mouse mannequin by deleting the promoter area and exon 1 of F8.
Donor DNA and CRISPR/SaCas9 had been packaged into AAV vectors and injected into HA mice intravenously. After remedy, F8 expression was restored and activated partial thromboplastin time (aPTT) was shortened. We additionally in contrast two liver-specific promoters and two forms of integrating donor vectors.
When an lively promoter was used, all the handled mice survived the tail-clip problem. That is the primary report of an in vivo gene restore technique with the potential to deal with a recurrent mutation in HA sufferers.
Carrot Supplementation Improves Blood Stress and Reduces Aortic Root Lesions in an Atherosclerosis-Susceptible Genetic Mouse Mannequin
Epidemiological research have proven that carrot consumption could also be related to a decrease threat of growing a number of metabolic dysfunctions. Our group beforehand decided that the Bolero (Bo) carrot selection exhibited vascular and hepatic tropism utilizing mobile fashions of cardiometabolic ailments.
The current research evaluated the potential metabolic and cardiovascular protecting impact of Bo, grown underneath two circumstances (commonplace and biotic stress circumstances (BoBS)), in apolipoprotein E-knockout (ApoE-/-) mice fed with excessive fats eating regimen (HFD).
Results on metabolic/hemodynamic parameters and on atherosclerotic lesions have been assessed. Each Bo and BoBS decreased plasma triglyceride and expression ranges of genes implicated in hepatic de novo lipogenesis and lipid oxidation. BoBS supplementation decreased physique weight achieve, secretion of very-low-density lipoprotein, and elevated cecal propionate content material.
Curiously, Bo and BoBS supplementation improved hemodynamic parameters by lowering systolic, diastolic, and imply blood strain. Furthermore, Bo improved cardiac output. Lastly, Bo and BoBS considerably diminished the aortic root lesion space.
These outcomes confirmed that Bo and BoBS enriched diets corrected a lot of the metabolic and cardiovascular issues in an atherosclerosis-prone genetic mouse mannequin and will subsequently signify an fascinating dietary method for the prevention of cardiovascular ailments.
Integration of Molecular Evaluation, Slicing-edge Mouse Genetic Fashions and Proton Remedy to Enhance Outcomes for Glioma Sufferers
Regardless of current advances on the whole most cancers remedy, glioblastoma stays among the many most deadly of human malignancies. Even with aggressive multimodal radiation and chemotherapy after surgical procedure, glioblastoma recurs with a bleak prognosis.
Many years of analysis centered on methods corresponding to rising radiation sensitivity and interference with oncogenic sign transduction have yielded solely incremental enhancements at finest. That is due partially to the radioresistance of glioblastoma and molecular heterogeneity of tumor cells.
We hypothesize is that the event of simpler glioblastoma therapies would require: (i) a extra correct molecular evaluation of glioblastoma in order to foretell response to remedy; (ii) higher genetically engineered mouse fashions, which may faithfully recapitulate human glioblastoma and the tumor microenvironment to check new approaches and (iii) growth and utility of extra correct and centered strategies to ship sustained excessive vitality particles to glioblastoma tumor websites.
This chapter describes the present state-of-the-art molecular evaluation approaches, newest in glioma mouse modelling, and advances within the utility of proton remedy remedy and analysis. By integrating primary and scientific analysis with cutting-edge applied sciences, a mechanistic understanding of glioblastoma remedy resistance and pathogenesis and the event of recent therapeutics to beat the therapeutic resistance of glioblastoma will probably be superior.
Altered neural oscillations and habits in a genetic mouse mannequin of NMDA receptor hypofunction
Abnormalities in electroencephalographic (EEG) biomarkers happen in sufferers with schizophrenia and people clinically at excessive threat for transition to psychosis and are related to cognitive impairment. Converging proof suggests N-methyl-D-aspartate receptor (NMDAR) hypofunction performs a central function within the pathophysiology of schizophrenia and sure contributes to biomarker impairments.
Thus, characterizing these biomarkers is of great curiosity for early analysis of schizophrenia and growth of novel remedies. We utilized in vivo EEG recordings and behavioral analyses to carry out a battery of electrophysiological biomarkers in a longtime mannequin of persistent NMDAR hypofunction, serine racemase knockout (SRKO) mice, and their wild-type littermates.
SRKO mice displayed impairments in investigation-elicited gamma energy that corresponded with diminished short-term social recognition and enhanced background (pre-investigation) gamma exercise. Moreover, SRKO mice exhibited sensory gating impairments in each evoked-gamma energy and event-related potential amplitude.
Nevertheless, different biomarkers together with the auditory steady-state response, sleep spindles, and state-specific energy spectral density had been typically neurotypical. In conclusion, SRKO mice display how persistent NMDAR hypofunction contributes to deficits in sure translationally-relevant EEG biomarkers altered in schizophrenia.
Bovine Placenta Growth Factor (PLGF) ELISA Kit |
|||
| DLR-PLGF-b-48T | DL Develop | 48T | EUR 591.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Bovine Placenta Growth Factor (PLGF) ELISA Kit |
|||
| DLR-PLGF-b-96T | DL Develop | 96T | EUR 769.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Placenta Growth Factor (PLGF) ELISA Kit |
|||
| DLR-PLGF-Hu-48T | DL Develop | 48T | EUR 404.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Placenta Growth Factor (PLGF) ELISA Kit |
|||
| DLR-PLGF-Hu-96T | DL Develop | 96T | EUR 511.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat Placenta Growth Factor (PLGF) ELISA Kit |
|||
| DLR-PLGF-Ra-48T | DL Develop | 48T | EUR 544.8 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat Placenta Growth Factor (PLGF) ELISA Kit |
|||
| DLR-PLGF-Ra-96T | DL Develop | 96T | EUR 704.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Bovine Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RD-PLGF-b-48Tests | Reddot Biotech | 48 Tests | EUR 592.8 |
Bovine Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RD-PLGF-b-96Tests | Reddot Biotech | 96 Tests | EUR 820.8 |
Human Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RD-PLGF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 381.6 |
Human Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RD-PLGF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 518.4 |
Rat Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RD-PLGF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 540 |
Rat Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RD-PLGF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 746.4 |
Bovine Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RDR-PLGF-b-48Tests | Reddot Biotech | 48 Tests | EUR 619.2 |
Bovine Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RDR-PLGF-b-96Tests | Reddot Biotech | 96 Tests | EUR 859.2 |
Human Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RDR-PLGF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 397.2 |
Human Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RDR-PLGF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 541.2 |
Rat Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RDR-PLGF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 564 |
Rat Placenta Growth Factor (PLGF) ELISA Kit |
|||
| RDR-PLGF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 781.2 |
Anti-PLGF antibody |
|||
| STJ72011 | St John's Laboratory | 100 µg | EUR 430.8 |
Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 418.8 |
Anti-PLGF/PGF Antibody |
|||
| PA1066 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-PLGF-2 Antibody |
|||
| A1303-100 | Biovision | each | EUR 405.6 |
Anti-PLGF-2 Antibody |
|||
| A1303-30T | Biovision | each | EUR 175.2 |
Mouse PLGF ELISA Kit |
|||
| EMP0025 | Abclonal | 96Tests | EUR 625.2 |
Polyclonal Goat Anti-PLGF Antibody |
|||
| AMM05090G | Leading Biology | 0.1 mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-PLGF . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
PlGF antibody |
|||
| 70R-12427 | Fitzgerald | 100 ug | EUR 523.2 |
|
Description: Rabbit polyclonal PlGF antibody |
|||
PLGF Peptide |
|||
| 42-184P | ProSci | 0.1 mg | EUR 405.6 |
|
Description: (IN) PLGF Peptide |
|||
PLGF protein |
|||
| 30R-2693 | Fitzgerald | 10 ug | EUR 390 |
|
Description: Purified recombinant Mouse PLGF protein |
|||
PLGF Antibody |
|||
| 49602-100ul | SAB | 100ul | EUR 399.6 |
PLGF Antibody |
|||
| 49602-50ul | SAB | 50ul | EUR 286.8 |
PLGF Antibody |
|||
| R30247 | NSJ Bioreagents | 100 ug | EUR 419 |
PLGF Antibody |
|||
| R34945-100UG | NSJ Bioreagents | 100 ug | EUR 399 |
PlGF Antibody |
|||
| 5743-100 | Biovision | each | EUR 405.6 |
PlGF Antibody |
|||
| 5743-30T | Biovision | each | EUR 175.2 |
Recombinant Mouse PLGF/PGF Protein |
|||
| RP01080 | Abclonal | 10 μg | EUR 280.8 |
PLGF Rabbit pAb |
|||
| A1727-100ul | Abclonal | 100 ul | EUR 369.6 |
PLGF Rabbit pAb |
|||
| A1727-200ul | Abclonal | 200 ul | EUR 550.8 |
PLGF Rabbit pAb |
|||
| A1727-20ul | Abclonal | 20 ul | EUR 219.6 |
PLGF Rabbit pAb |
|||
| A1727-50ul | Abclonal | 50 ul | EUR 267.6 |
PLGF Rabbit pAb |
|||
| A16257-100ul | Abclonal | 100 ul | EUR 369.6 |
PLGF Rabbit pAb |
|||
| A16257-200ul | Abclonal | 200 ul | EUR 550.8 |
PLGF Rabbit pAb |
|||
| A16257-20ul | Abclonal | 20 ul | EUR 219.6 |
PLGF Rabbit pAb |
|||
| A16257-50ul | Abclonal | 50 ul | EUR 267.6 |
PlGF Recombinant Protein |
|||
| 96-625 | ProSci | 0.02 mg | EUR 651.3 |
|
Description: Placental growth factor (PGF) is also known as vascular endothelial growth factor-related protein, PLGF and PlGF2, is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PGF during pregnancy is the placental trophoblast. PGF is also expressed in many other tissues, including the villous trophoblast. PGF is actived in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. PlGF2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth. |
|||
PLGF(PLGF93) Antibody |
|||
| BNC040093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC040093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC040094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC040094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC050093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC050093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC050094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC050094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCAP0093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCAP0093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCAP0094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCAP0094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCB0093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCB0093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCB0094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCB0094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCP0093-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCP0094-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCR0093-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCR0094-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC940093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC940093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC940094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC940094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCA0093-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCA0094-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC810093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC810093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC810094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC810094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNUB0093-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNUB0093-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNUB0094-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNUB0094-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCH0093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNCH0093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCH0094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNCH0094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC880093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC880093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC880094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC880094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PLGF Conjugated Antibody |
|||
| C49602 | SAB | 100ul | EUR 476.4 |
PLGF(PLGF93) Antibody |
|||
| BNC680093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC680093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC680094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC680094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC470093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC470093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC470094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC470094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC430093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC430093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC430094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC430094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC610093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC610093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC610094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC610094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC800093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC800093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC800094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC800094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC400093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC400093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC400094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC400094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC550093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC550093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC550094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC550094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC700093-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF93) Antibody |
|||
| BNC700093-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC700094-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNC700094-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Polyclonal PlGF Antibody |
|||
| AMR09382G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PlGF . This antibody is tested and proven to work in the following applications: |
|||
PLGF(PLGF93) Antibody |
|||
| BNUM0093-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against PLGF(PLGF93), 1mg/mL |
|||
PLGF(PLGF94) Antibody |
|||
| BNUM0094-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against PLGF(PLGF94), 1mg/mL |
|||
PLGF Polyclonal Antibody |
|||
| A72122-050 | EpiGentek | 50 ul | EUR 302.5 |
PLGF Polyclonal Antibody |
|||
| A72122-100 | EpiGentek | 100 ul | EUR 423.5 |
PLGF Polyclonal Antibody |
|||
| A72123-050 | EpiGentek | 50 ul | EUR 302.5 |
PLGF Polyclonal Antibody |
|||
| A72123-100 | EpiGentek | 100 ul | EUR 423.5 |
PLGF Polyclonal Antibody |
|||
| A72122 | EpiGentek |
|
|
Importantly, our gamma band findings counsel an aberrant signal-to-noise ratio impairing cognition that happens with NMDAR hypofunction, doubtlessly tied to impaired task-dependent alteration in useful connectivity.
